Immunovant (IMVT) Enterprise Value (2019 - 2026)

Immunovant (IMVT) has 9 years of Enterprise Value data on file, last reported at -$902.1 million in Q1 2026.

• Quarterly Enterprise Value fell 26.35% year-over-year to -$902.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$902.1 million (down 26.35% YoY) and the FY2026 annual result came in at -$902.1 million, down 26.35% from the prior year.
• Enterprise Value grew to -$902.1 million in Q1 2026, from -$994.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$269.9 million in Q3 2023 to a low of -$994.5 million in Q4 2025.
• A 5-year average of -$541.2 million and a median of -$493.8 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 45.77% — and 2025, when it sank 165.42%.
• Tracing IMVT's Enterprise Value over 5 years: stood at -$432.6 million in 2022, then plunged by 59.71% to -$690.9 million in 2023, then jumped by 45.77% to -$374.7 million in 2024, then slumped by 165.42% to -$994.5 million in 2025, then climbed by 9.29% to -$902.1 million in 2026.
• The last three Enterprise Value figures came in at -$902.1 million (Q1 2026), -$994.5 million (Q4 2025), and -$521.9 million (Q3 2025), per Business Quant data.